Old biliverdin reductase: Links to insulin resistance and may be a novel therapeutic target

Medical Hypotheses

Volumn 71, Issue 1, 2008, Pages 73-76

  Wu, Bin ^a   Liu, Xiaoyan ^b   Shen, Jinfang ^b  

^a SHANGHAI JIAO TONG UNIVERSITY AFFILIATED SIXTH PEOPLE S HOSPITAL   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BILIVERDIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN RECEPTOR SUBSTRATE 1;

ARTICLE; DRUG TARGETING; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; METABOLIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; ANTIOXIDANTS; DIABETES MELLITUS, TYPE 2; HUMANS; INSULIN RESISTANCE; MODELS, BIOLOGICAL; OXIDOREDUCTASES ACTING ON CH-CH GROUP DONORS; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION;

EID: 43949135165     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2008.02.007     Document Type: Article

References (35)

1. Kashyap S.R., and Defronzo R.A. The insulin resistance syndrome: physiological considerations. Diab Vasc Dis Res 4 (2007) 13-19
2. Park S.M., Lim M.K., Jung K.W., et al. Prediagnosis smoking, obesity, insulin resistance and second primary cancer risk in male cancer survivors: National Health Insurance Corporation Study. J Clin Oncol 25 (2007) 4835-4843
3. Mlinar B., Marc J., Janez A., and Pfeifer M. Molecular mechanisms of insulin resistance and associated diseases. Clin Chim Acta; Int J Clin Chem 375 (2007) 20-35
4. Bloomgarden Z.T. Insulin resistance concepts. Diab Care 30 (2007) 1320-1326
5. Bhattacharya S., Dey D., and Roy S.S. Molecular mechanism of insulin resistance. J Biosci 32 (2007) 405-413
6. Singleton J.W., and Laster L. Biliverdin reductase of guinea pig liver. J Biol Chem 240 (1965) 4780-4789
7. Colleran E., and Carra P.O. Specificity of biliverdin reductase. Biochem J 119 (1970) 16P-17P
8. Florczyk U.M., Jozkowicz A., and Dulak J. Biliverdin reductase: new features of an old enzyme and its potential therapeutic significance. Pharmacol Rep 60 (2008) 38-48
9. Maines M.D., and Trakshel G.M. Purification and characterization of human biliverdin reductase. Arch Biochem Biophys 300 (1993) 320-326
10. Maines M.D. Biliverdin reductase: PKC interaction at the cross-talk of MAPK and PI3K signaling pathways. Antioxidants Redox Signal 9 (2007) 2187-2195
11. Li L.F., and Li J. Link between oxidative stress and insulin resistance. Chin Med Sci J = Chung-kuo i hsueh k'o hsueh tsa chih/Chin Acad Med Sci 22 (2007) 254-259
12. Meigs J.B., Larson M.G., Fox C.S., Keaney Jr. J.F., Vasan R.S., and Benjamin E.J. Association of oxidative stress, insulin resistance, and diabetes risk phenotypes: the Framingham Offspring Study. Diab Care 30 (2007) 2529-2535
13. Evans J.L., Maddux B.A., and Goldfine I.D. The molecular basis for oxidative stress-induced insulin resistance. Antioxidants Redox Signal 7 (2005) 1040-1052
14. Houstis N., Rosen E.D., and Lander E.S. Reactive oxygen species have a causal role in multiple forms of insulin resistance. Nature 440 (2006) 944-948
15. Sedlak T.W., and Snyder S.H. Bilirubin benefits: cellular protection by a biliverdin reductase antioxidant cycle. Pediatrics 113 (2004) 1776-1782
16. Baranano D.E., Rao M., Ferris C.D., and Snyder S.H. Biliverdin reductase: a major physiologic cytoprotectant. Proc Nat Acad Sci USA 99 (2002) 16093-16098
17. Liu Y., Liu J., Tetzlaff W., Paty D.W., Cynader M.S., reductase B., et al. suppresses experimental autoimmune encephalomyelitis. Free Rad Biol Med 40 (2006) 960-967
18. Miralem T., Hu Z., Torno M.D., Lelli K.M., and Maines M.D. Small interference RNA-mediated gene silencing of human biliverdin reductase, but not that of heme oxygenase-1, attenuates arsenite-mediated induction of the oxygenase and increases apoptosis in 293A kidney cells. J Biol Chem 280 (2005) 17084-17092
19. Muoio D.M., and Newgard C.B. Mechanisms of disease: Molecular and metabolic mechanisms of insulin resistance and beta-cell failure in type 2 diabetes. Nat Rev Mol Cell Biol (2008)
20. Pessin J.E., and Saltiel A.R. Signaling pathways in insulin action: molecular targets of insulin resistance. J Clin Invest 106 (2000) 165-169
21. Draznin B. Molecular mechanisms of insulin resistance: serine phosphorylation of insulin receptor substrate-1 and increased expression of p85alpha: the two sides of a coin. Diabetes 55 (2006) 2392-2397
22. White M.F. Insulin signaling in health and disease. Science (New York, NY) 302 (2003) 1710-1711
23. Shah O.J., Wang Z., and Hunter T. Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies. Curr Biol 14 (2004) 1650-1656
24. Qiao L.Y., Zhande R., Jetton T.L., Zhou G., and Sun X.J. In vivo phosphorylation of insulin receptor substrate 1 at serine 789 by a novel serine kinase in insulin-resistant rodents. J Biol Chem 277 (2002) 26530-26539
25. Carvalho E., Jansson P.A., Axelsen M., et al. Low cellular IRS 1 gene and protein expression predict insulin resistance and NIDDM. Faseb J 13 (1999) 2173-2178
26. Tremblay F., Brule S., Hee Um S., et al. Identification of IRS-1 Ser-1101 as a target of S6K1 in nutrient- and obesity-induced insulin resistance. Proc Nat Acad Sci USA 104 (2007) 14056-14061
27. Huang X., Vaag A., Hansson M., and Groop L. Down-regulation of insulin receptor substrates (IRS)-1 and IRS-2 and Src homologous and collagen-like protein Shc gene expression by insulin in skeletal muscle is not associated with insulin resistance or type 2 diabetes. J Clin Endocrinol Metabol 87 (2002) 255-259
28. Lerner-Marmarosh N., Shen J., Torno M.D., Kravets A., Hu Z., and Maines M.D. Human biliverdin reductase: a member of the insulin receptor substrate family with serine/threonine/tyrosine kinase activity. Proc Nat Acad Sci USA 102 (2005) 7109-7114
29. Brachmann S.M., Ueki K., Engelman J.A., Kahn R.C., and Cantley L.C. Phosphoinositide 3-kinase catalytic subunit deletion and regulatory subunit deletion have opposite effects on insulin sensitivity in mice. Mol Cell Biol 25 (2005) 1596-1607
30. Ueki K., Fruman D.A., Brachmann S.M., Tseng Y.H., Cantley L.C., and Kahn C.R. Molecular balance between the regulatory and catalytic subunits of phosphoinositide 3-kinase regulates cell signaling and survival. Mol Cell Biol 22 (2002) 965-977
31. Mauvais-Jarvis F., Ueki K., Fruman D.A., et al. Reduced expression of the murine p85alpha subunit of phosphoinositide 3-kinase improves insulin signaling and ameliorates diabetes. J Clin Invest 109 (2002) 141-149
32. Barbour L.A., Mizanoor Rahman S., Gurevich I., et al. Increased P85alpha is a potent negative regulator of skeletal muscle insulin signaling and induces in vivo insulin resistance associated with growth hormone excess. J Biol Chem 280 (2005) 37489-37494
33. Bandyopadhyay G.K., Yu J.G., Ofrecio J., and Olefsky J.M. Increased p85/55/50 expression and decreased phosphotidylinositol 3-kinase activity in insulin-resistant human skeletal muscle. Diabetes 54 (2005) 2351-2359
34. Terauchi Y., Tsuji Y., Satoh S., et al. Increased insulin sensitivity and hypoglycaemia in mice lacking the p85 alpha subunit of phosphoinositide 3-kinase. Nat Gen 21 (1999) 230-235
35. Pachori A.S., Smith A., McDonald P., Zhang L., Dzau V.J., and Melo L.G. Heme-oxygenase-1-induced protection against hypoxia/reoxygenation is dependent on biliverdin reductase and its interaction with PI3K/Akt pathway. J Mol Cell Cardiol 43 (2007) 580-592